摘要
目的：比较单纯化学药物治疗（化疗）方案与化疗联合靶向治疗（贝伐单抗或西妥昔单抗）对于治疗晚期结直肠癌的疗效及安全性的差异，以指导临床用药。方法：在Pubmed，Embase，中国期刊全文数据库，万方以及重庆维普数据库中搜索各种化疗方案及其联合靶向药物治疗晚期结直肠癌的临床研究。对纳入的文章逐篇进行质量评估。采用Meta分析软件ReviewManager5．1．7对化疗与化疗联合靶向治疗结直肠癌的疗效及安全性进行系统评价。结果：共有11篇文献纳入Meta分析。在总缓解率（完全缓解＋部分缓解）方面，化疗联合靶向治疗组明显优于单纯化疗组（OR=0．48，95％CI：0．37—0．63，P〈0．001）。恶心呕吐、腹泻、肝损害、骨髓抑制、神经系统不良反应等不良反应中，两组差异无统计学意义（P〉0．05）。结论：在中国晚期结直肠癌患者中，化疗联合靶向治疗的疗效明显优于单纯化疗，但不良反应发生率二者无明显差别。
Objective： To compare the difference of efficacy and safety between the chemotherapies and the chemotherapies combined with targeted drugs in advanced colorectal cancer. Methods： Pubmed, Embase, CNKI, Wanfang database, and VIP database were used to search a variety of chemotherapy regimens and their co-targeted drug therapy in advanced colorectal cancer. A systematic review of comparing chemotherapy plus targeted therapy with chemotherapy alone was conducted by Meta-analysis software Review Manager 5.1.7. Remits： Eleven trials and 973 patients in total were analyzed in this meta-analysis. The overall response rate （CR＋PR） of the chemotherapy combined with targeted drugs was obviously higher than that of the chemotherapy alone （OR=0.48, 95% CI：0.37- 0.63, P〈0.001）. No difference in the five adverse reactions （nausea, vomiting, diarrhea, liver damage, bone marrow suppression, and neurotoxicity） was found between the chemotherapy combined with targeted drugs and the chemotherapy alone （P〉0.05）. Conclusion In the advanced colorectal cancer in Chinese patients, the efficacy of the chemotherapy combined with targeted drugs is more dominant than chemotherapy alone. The adverse reactions are not revealed any significant differences in the 2 therapy methods
出处
《国际病理科学与临床杂志》
CAS
2013年第1期28-36,共9页
Journal of International Pathology and Clinical Medicine
基金
北京市"215"高层次卫生人才资助项目(2011-2014)
北京市"十百千"人才资助项目(2011-2013)
首都医科大学本科生科研创新项目(2012-2013)~~
